With an aging population, surging rates of obesity, and the incidence of diabetes on the rise, these 14 companies are exploring cell therapy treatments for diabetes. According to the Center for Disease Control (CDC), 29.1 million people or 9.3% of the U.S. population has diabetes, including an estimated 8.1 million who are undiagnosed. According to the American Diabetes Association, the 2012 cost of this disease in the U.S. was “$245 billion per annum or approximately $500,000 every minute.”
Fortunately, progress with cell therapy treatments for diabetes is being made by companies and institutions worldwide. In a historic achievement, the Diabetes Research Institute a Center of Excellence at the University of Miami Miller School of Medicine announced the first diabetic patient in its clinical trial had stopped insulin therapy after the implantation of islet cells within a biological scaffold. Other innovative approaches to the treatment of diabetes are explored below.
Companies Developing Cell Therapies for Diabetes
In this article:
- Betalin Therapeutics
- NextCell Pharma AB
- Osiris Therapeutics
- Evotec and Sanofi
- Semma Therapeutics
- Novo Nordisk
- Eli Lilly and Sigilon
Cell Therapy Treatments for Diabetes
Given the growing promise of regenerative medicine, the following companies are exploring cell therapies for the treatment for diabetes.
1. Unicyte AG | Diabetes Cell Therapy
Unicyte has established a collaboration with Prof Giovanni Camussi from Molecular Biotechnology Center (MBC) at the University of Turin. Through this alliance, Unicyte has developed three proprietary technology platforms:
- Human Liver Stem Cells (HLSCs)
- HLSC-derived Functional Pancreatic Islets
- Nano-Extracellular Vesicles
As stated by Unicyte, “Prof Giovanni Camussi recently discovered that Human Liver Stem Cells (HLSCs) are able to undergo differentiation into insulin secreting cells. Moreover, HLSCs have been shown to aggregate and form three dimensional spherical structures resembling natural islets. HLSC-Islets secrete insulin and are positive for various hormones including glucagon, grehlin, and somatostatin. When injected into animal models of type 1 diabetes, these islet-like structures are fully functional and restore glycemic control.”
2. ViaCyte | Insulin for Diabetes
In February 2016, San Diego based ViaCyte acquired an exclusive license to “BetaLogics intellectual property in the field of metabolic disease, including diabetes, and the transfer of related assets to ViaCyte.” The news positioned ViaCyte as a leader in stem cell therapeutics for the treatment of Type 1 and 2 diabetes.
According to Dr. Paul Laikind, ViaCyte’s President and CEO, “For more than a decade, BetaLogics and ViaCyte have been independently working toward a stem cell-derived therapy for diabetes. By combining the intellectual property and other assets of BetaLogics with ViaCyte, we will further strengthen our advanced program focused on insulin-dependent diabetes and solidify our leadership in the field.”
According to ViaCyte, it differentiates stem cells into pancreatic beta cell precursors (PEC-01™) and subcutaneously implants them into patients using a retrievable medical device (an Encaptra® cell delivery system), allowing the implanted precursor cells to mature into endocrine cells that can secrete insulin and other hormones in a controlled manner to support healthy blood glucose levels.
3. Sernova | Diabetes Treatment
In September 2015, Sernova Corporation secured exclusive worldwide rights to patent-pending technologies developed by researchers at the University Health Network (UHN) in Canada, with the license giving them the capacity to turn stem cells into glucose-responsive therapeutic cells for use in the treatment of insulin-dependent diabetes.
According to Sernova’s CEO, “This agreement provides us with a proprietary source of stem cell-derived glucose responsive therapeutic cells. When placed within Sernova’s prevascularized Cell Pouch(TM), and protected locally from immune system attack, we believe that Sernova has the potential to provide a significant breakthrough in the quality of treatment for the millions of people suffering from insulin-dependent diabetes.”
In January 2016, Sernova then announced a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to “establish, optimize and validate Sernova’s licensed technology for creating stem cell-derived therapeutic cells that produce insulin and are glucose responsive.”
4. Betalin Therapeutics | Insulin Production
Betalin Therapeutics, Ltd., based in Ramat Gan, Israel, is led by Mr. Jacob Ben-Arie (CEO). The company is developing the Engineered Micro Pancreas (EMP), a breakthrough technology that will enable it to implant pancreatic cells, which include insulin-producing cells to restore the body’s intrinsic insulin generation capabilities. This miniature pancreas is implanted in the patients’ body under the skin, using a local anesthesia with minimal risk to the patient and costs of the procedure.
Betalin has acquired technology that is based on the premise that in order for beta cells to function properly, it is necessary to provide an appropriate stromal (connective tissue) microenvironment. In its first phase, Betalin will use the platform technology to create engineered micro pancreata (EMPs) composed of naked islets (Io) and micro-scaffolds. EMPs will be used instead of naked islets in islet transplantation therapy to provide significant levels of glucose-regulated insulin secretion over extended periods of time.
5. AltuCell | Treatment for Type 2 Diabetes
A small but powerful company working in this area is AltuCell, a company whose mission is to find a cure for insulin-dependent diabetes. Led by CEO Gary Harlem, AltuCell is a private pharmaceutical company with a world-renowned medical team spread across the U.S. and Europe. In a recent peer-review article published in the journal Xenotransplantation on Sept. 27th 2016, AltuCell’s medical lead, Dr. Giovanni Luca, announced:
“In this study, the Calafiore group has transplanted microencapsulated porcine Sertoli cells into the subcutaneous fat of 30 type 2 diabetic-prone obese mice (db/db) after they had become frankly diabetic. Remarkably, 60% of the treated mice (18 out of the 30) had their glucose control restored and demonstrated normal glucose tolerance tests. The remaining 40% “failures” all showed improvements as assessed by reduced HbA1c levels. Control mice remained diabetic.”
AltuCell’s preclinical breakthrough utilizing microencapsulated Sertoli cells to establish reversal of diabetes in a murine (mouse) mode is further highlighted in the article “Altucell Releases Evidence in Support of Microencapsulated Sertoli Cells for Reversal of Diabetes.”
6. NextCell Pharma AB | Type 1 Diabetes Treatment
In July 2017, Stockholm based NextCell Pharma submitted an application to the Medical Products Agency for a clinical trial in autoimmune diabetes with its stem cell product ProTrans™. Protrans™ is composed of stem cells derived from the umbilical cord tissue and intended for use in the treatment of inflammatory and autoimmune diseases.
More recently, NextCell Pharma AB announced on September 5, 2017, that its clinical trial application for ProTrans™ had been granted by the Ethics Committee. The clinical trial is designed to evaluate the safety of ProTrans™, as well as its ability to positively affect endogenous insulin production in adult Type 1 Diabetes patients.
7. Osiris Therapeutics | Type 1 Diabetes Control
Osiris Therapeutics is exploring the use of its Prochymal cell therapy for multiple indications, including the treatment of diabetes. In 2014, Osiris completed a Phase II Type 1 Diabetes clinical trial that evaluated the efficacy and safety of Prochymal. Titled “PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM),” the clinical trial was completed December 2014. Prochymal is an adult human mesenchymal stem cell (MSC) product that may delay the progression of type 1 diabetes by preserving beta cell function, and therefore, insulin production.
8. Mesoblast | Type 2 Diabetes Treatment
Mesoblast Limited is exploring the use of its human mesenchymal progenitor cells (MPC) product for the treatment of Type 2 Diabetes. It first demonstrated the efficacy of its product in preclinical trials when an injection of MPCs into diabetic mice produced an increase in blood insulin levels and a reduction in blood glucose levels.
Mesoblast then moved into clinical trials, publishing the results of its Phase 2 trial of its intravenously (IV) administered MPCs for the treatment of type 2 diabetes in Diabetes Care, a journal of the American Diabetes Association (ADA). Titled “Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose Escalation Safety and Tolerability Pilot Study,” it was the first controlled trial to investigate cell therapy using adult allogeneic mesenchymal lineage cells in subjects with type 2 diabetes. Furthermore, it demonstrated the safety and feasibility of leveraging MPCs in subjects with type 2 diabetes.
9. Evotec and Sanofi | Stem Cell Treatment Diabetes
In, August 2015 that Evotec and Sanofi entered into a strategic alliance to develop a beta cell replacement therapy for diabetes. The partnership is focused on using human induced pluripotent stem cells (hiPS cells) to create functional human beta cells. According to the companies, “The agreement between Evotec and Sanofi triggers an upfront payment of € 3 m, potential pre-clinical, clinical, regulatory and commercial milestones which could total over € 300 m as well as significant royalties and research payments.”
10. Orgenesis | Insulin Producing Cells
Orgenesis Ltd. is developing a proprietary and patented platform technology called “transdifferentiation” in which an adult cell is converted into another type of cell. Using this technology, the company is producing Autologous Insulin Producing (“AIP”) cells that may have the capacity to turn the liver cells of diabetic patients into “fully functional and physiologically glucose-responsive insulin-producing cell, designed to provide long-term insulin independence.”
11. Semma Therapeutics | Type 1 Diabetes Therapy
Semma Therapeutics is commercializing technology from the laboratory of Professor Douglas Melton, who discovered a method to producing billions of functional, insulin-producing beta cells within a laboratory context. According to Semma, initial preclinical work in animal models of diabetes has shown that transplantation of these cells can support healthy blood glucose levels.
In December 2017, Semma Therapeutics announced it had raised $114 million in a Series B financing. The company will use the funds to pursue proof-of-concept studies for its stem cell-derived beta cells, a potential therapy for people living with type 1 diabetes. Semma is also preparing to file an investigational new drug (IND) application for its beta-cell program, as well as exploring other applications for its technologies.
12. Novo Nordisk | Treatment of Type 1 Diabetes
In May 2018, Novo Nordisk announced an increased focus on stem cell-based therapies and expansion of its focus on type 1 diabetes. The company has an exclusive collaboration with the University of California San Francisco and has reached the first milestone in the development of its human embryonic stem cell (hESC) lines.
Additionally, Novo is collaborating with Cornell University to address impediments to the use of stem cells in the treatment of Type 1 diabetes, by creating an encapsulation device to prevent the recognition of beta cells by the host’s immune system.
13. Beta-O2 | Artificial Pancreas for Diabetes
Beta-O2 is developing the ßAir Bio-artificial Pancreas, intended to cure Type 1 diabetes (TID). Developed by Beta-O2, ßAir provides an environment that allows insulin producing beta cells to survive within the patient’s body and supply insulin. Because ßAir protects the islet cells from the body’s immune system without the need for immunosuppressive drugs, it can utilize cells from a variety of sources, including human donors, animals (pigs), and or stem cell derivatives.
14. Eli Lilly and Sigilon | Stem Cell Therapy Diabetes
In April 2018, Eli Lilly and Company and Sigilon Therapeutics announced a partnership to co-develop encapsulated cell therapies for the treatment of type 1 diabetes. Under the partnership, Sigilon will create proprietary products using induced pluripotent stem cells (iPS cells) that are differentiated into insulin-producing pancreatic beta cells and encapsulated using Sigilon’s Afibromer technology. The goal of this cell therapy approach is to restore insulin production over sustained periods without triggering an immune reaction.
Sigilon is a privately-held biotech company that is developing “living therapeutics” with its Afibromer™ technology product platform, while Lilly is a global biopharmaceutical company and a worldwide leader in diabetes care.
Companies Developing Cell Therapies for Diabetes?
What other companies are conducting research to treat diabetes using stem cells? Share your thoughts in the comments section below and we will add them.
BioInformant is the first and only market research firm to specialize in the stem cell industry. Our research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving industry leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson. BioInformant is your global leader in stem cell industry data.